

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

POZEN INC. and HORIZON PHARMA USA, INC.,
Patent Owners

U.S. Patent No. 9,220,698

Inter Partes Review IPR2017-01995

**DECLARATION OF MICHAEL MAYERSOHN, PH.D.
IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF U.S.
PATENT NO. 9,220,698**

TABLE OF CONTENTS

	Page
I. Introduction.....	5
II. Qualifications and Background	5
A. Education and Experience	5
B. Bases for Opinions	8
C. Retention and Compensation	8
III. Legal Standards	8
IV. Definition of a Person of Ordinary Skill in the Art (POSA).....	10
V. Summary of Opinions.....	11
VI. Background on Pharmacokinetics and Pharmacodynamics	12
VII. U.S. Patent No. 9,220,698 [Ex. 1001]	21
A. The '698 Patent Specification	22
B. The Challenged Claims	33
VIII. Claim Construction.....	36
A. Legal Standard.....	36
B. The Term “Target” Means “With The Goal of Obtaining”	37
IX. The Prior Art.....	42
A. Prior Art References Disclosed A Combined Dosage Form With Naproxen and Esomeprazole.....	42
(a) U.S. Patent No. 8,557,285 (“285 Patent”) [Ex. 1005].....	43
(b) U.S. Patent No. 6,926,907 (“907 Patent”) [Ex. 1004].....	45
(c) Goldstein [Ex. 1011].....	47
(d) Hochberg [Ex. 1012].....	48
(e) Hassan-Alin [Ex. 1016]	50
B. Prior art references disclosed the target pharmacokinetics of naproxen	52
(a) EC-Naprosyn label [Ex. 1009].....	52

TABLE OF CONTENTS
(continued)

	Page
(b) Khosravan [Ex. 1017]	53
(c) Jung [Ex. 1018]	54
(d) Davies [Ex. 1019]	55
C. Prior Art References Disclosed The Target Pharmacokinetics of, and Pharmacodynamic Response To, Esomeprazole	56
(a) Howden 2005 [Ex. 1006]	56
(b) Zegerid label [Ex. 1010]	57
D. Esomeprazole is a Component of Omeprazole	59
X. All Claims of the '698 Patent Are Unpatentable.....	60
A. The '285 Patent Anticipated the Claims of the '698 Patent.....	60
(a) The '285 Patent anticipated independent claim 1	60
1. The '285 patent taught a combined dosage form of naproxen and esomeprazole and its twice daily administration.	62
2. The PK/PD elements are inherent in the twice- daily administration of the dosage forms disclosed in the '285 patent.	63
(b) Dependent claim 2 was anticipated	66
(c) Dependent claims 3 and 4 were anticipated.....	66
(d) Dependent claims 5-7 were anticipated	67
B. Ground 2: U.S. Patent No. 8,557,285 Rendered Obvious the Claims of the '698 Patent.....	69
(a) The pharmacokinetic and pharmacodynamic properties of the claimed unit dose form would have been obvious.....	69
(b) Dependent claim 2 would have been obvious	71
(c) Dependent claims 3 and 4 would have been obvious.....	72
(d) Dependent claims 5-7 would have been obvious	73

TABLE OF CONTENTS
(continued)

	Page
C. Ground 3: U.S. Patent No. 8,557,285, in View of Howden 2005 and the EC-Naprosyn Label, Rendered Obvious the Claims of the '698 Patent.....	75
(a) Independent claim 1 would have been obvious	75
1. The prior art provided motivation to target (i.e., have the goal of obtaining) the PK and PD elements.	76
2. The prior art provided a reasonable expectation of success in setting the PK and PD elements as targets.....	88
(b) Dependent claim 2 would have been obvious	90
(c) Dependent claims 3-4 would have been obvious	90
(d) Dependent claims 5-7 would have been obvious	92
D. There Are No Unexpected Results Arising From The Claimed Method.....	94

I, Michael Mayersohn, Ph.D., do hereby declare:

I. Introduction

1. My name is Michael Mayersohn. I have been retained by Mylan Pharmaceuticals Inc. (“Mylan”) in the matter set forth in the caption above. I understand that Mylan is petitioning for *inter partes* review (“IPR”) of claims 1-7 of U.S. Patent No. 9,220,698 to Ault *et al.* (“the ’698 patent”) [Ex. 1001]. I submit this expert declaration in support of Mylan’s IPR petition for the ’698 patent.

II. Qualifications and Background

A. Education and Experience

2. I am Professor Emeritus of Pharmaceutical Sciences in the College of Pharmacy at the University of Arizona, in Tucson, Arizona.

3. I earned my Bachelor of Science degree in Pharmacy from the College of Pharmaceutical Sciences at Columbia University, in New York, in 1966. I earned a Ph.D. in Pharmaceutics from the State University of New York at Buffalo, in 1970. From 1971 until 1976, I was an assistant and then an associate professor in the Faculty of Pharmacy at the University of Toronto. In 1976, I joined the faculty of the University of Arizona, as an associate professor in the College of Pharmacy. In 1983, I became a professor in the University of Arizona College of Pharmacy, and am currently a Professor Emeritus there.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.